A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis
Latest Information Update: 24 Jul 2024
At a glance
- Drugs MuSK-CAART (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; First in man
- Acronyms MusCAARTes
- Sponsors Cabaletta Bio
- 15 May 2024 According to a Cabaletta Bio media release, trial is currently not dosing patients as clinical and translational data from the A1 and A2 cohorts is being evaluated.
- 10 Aug 2023 According to a Cabaletta Bio media release, based on emerging data from the DesCAARTes study, clinical trial timelines are under evaluation for this Phase 1, open-label MusCAARTes study.
- 16 Mar 2023 According to a Cabaletta Bio media release, trial design published in Nature Biotechnology.